Cargando…

An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients

BACKGROUND: Pseudogenes show multiple functions in various cancer types, and immunotherapy is a promising cancer treatment. Therefore, this study aims to identify immune-related pseudogene signature in endometrial cancer (EC). METHODS: Gene transcriptome data of EC tissues and corresponding clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Shanshan, Zhuge, Yiyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243762/
https://www.ncbi.nlm.nih.gov/pubmed/34193185
http://dx.doi.org/10.1186/s12938-021-00902-7
_version_ 1783715810842247168
author Tang, Shanshan
Zhuge, Yiyi
author_facet Tang, Shanshan
Zhuge, Yiyi
author_sort Tang, Shanshan
collection PubMed
description BACKGROUND: Pseudogenes show multiple functions in various cancer types, and immunotherapy is a promising cancer treatment. Therefore, this study aims to identify immune-related pseudogene signature in endometrial cancer (EC). METHODS: Gene transcriptome data of EC tissues and corresponding clinical information were downloaded from The Cancer Genome Atlas (TCGA) through UCSC Xena browser. Spearman correlation analysis was performed to identify immune-related pseudogenes (IRPs) between the immune genes and pseudogenes. Univariate Cox regression, LASSO, and multivariate were performed to develop a risk score signature to investigate the different overall survival (OS) between high- and low-risk groups. The prognostic significance of the signature was assessed by the Kaplan–Meier curve, time-dependent receiver operating characteristic (ROC) curve. The abundance of 22 immune cell subtypes of EC patients was evaluated using CIBERSORT. RESULTS: Nine IRPs were used to build a prognostic signature. Survival analysis revealed that patients in the low-risk group presented longer OS than those in the high-risk group as well as in multiple subgroups. The signature risk score was independent of other clinical covariates and was associated with several clinicopathological variables. The prognostic signature reflected infiltration by multiple types of immune cells and revealed the immunotherapy response of patients with anti-programmed death-1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) therapy. Function enrichment analysis revealed that the nine IRPs were mainly involved in multiple cancer-related pathways. CONCLUSION: We identified an immune-related pseudogene signature that was strongly correlated with the prognosis and immune response to EC. The signature might have important implications for improving the clinical survival of EC patients and provide new strategies for cancer treatment.
format Online
Article
Text
id pubmed-8243762
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82437622021-06-30 An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients Tang, Shanshan Zhuge, Yiyi Biomed Eng Online Research BACKGROUND: Pseudogenes show multiple functions in various cancer types, and immunotherapy is a promising cancer treatment. Therefore, this study aims to identify immune-related pseudogene signature in endometrial cancer (EC). METHODS: Gene transcriptome data of EC tissues and corresponding clinical information were downloaded from The Cancer Genome Atlas (TCGA) through UCSC Xena browser. Spearman correlation analysis was performed to identify immune-related pseudogenes (IRPs) between the immune genes and pseudogenes. Univariate Cox regression, LASSO, and multivariate were performed to develop a risk score signature to investigate the different overall survival (OS) between high- and low-risk groups. The prognostic significance of the signature was assessed by the Kaplan–Meier curve, time-dependent receiver operating characteristic (ROC) curve. The abundance of 22 immune cell subtypes of EC patients was evaluated using CIBERSORT. RESULTS: Nine IRPs were used to build a prognostic signature. Survival analysis revealed that patients in the low-risk group presented longer OS than those in the high-risk group as well as in multiple subgroups. The signature risk score was independent of other clinical covariates and was associated with several clinicopathological variables. The prognostic signature reflected infiltration by multiple types of immune cells and revealed the immunotherapy response of patients with anti-programmed death-1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) therapy. Function enrichment analysis revealed that the nine IRPs were mainly involved in multiple cancer-related pathways. CONCLUSION: We identified an immune-related pseudogene signature that was strongly correlated with the prognosis and immune response to EC. The signature might have important implications for improving the clinical survival of EC patients and provide new strategies for cancer treatment. BioMed Central 2021-06-30 /pmc/articles/PMC8243762/ /pubmed/34193185 http://dx.doi.org/10.1186/s12938-021-00902-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tang, Shanshan
Zhuge, Yiyi
An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients
title An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients
title_full An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients
title_fullStr An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients
title_full_unstemmed An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients
title_short An immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients
title_sort immune-related pseudogene signature to improve prognosis prediction of endometrial carcinoma patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243762/
https://www.ncbi.nlm.nih.gov/pubmed/34193185
http://dx.doi.org/10.1186/s12938-021-00902-7
work_keys_str_mv AT tangshanshan animmunerelatedpseudogenesignaturetoimproveprognosispredictionofendometrialcarcinomapatients
AT zhugeyiyi animmunerelatedpseudogenesignaturetoimproveprognosispredictionofendometrialcarcinomapatients
AT tangshanshan immunerelatedpseudogenesignaturetoimproveprognosispredictionofendometrialcarcinomapatients
AT zhugeyiyi immunerelatedpseudogenesignaturetoimproveprognosispredictionofendometrialcarcinomapatients